PH-DyPred: A Multimodal Dynamic Risk Prediction Study in Pulmonary Hypertension
Recruiting
Observational Study
Pulmonary Hypertension
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 1,000 (estimated)
- Sponsor
- First Affiliated Hospital of Fujian Medical University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Pulmonary hypertension (PH) is a progressive cardiopulmonary disease characterized by elevated pulmonary artery pressure and vascular remodeling, which leads to right heart failure and increased mortality. Despite advances in diagnostics, risk stratification remains limited due to the disease's heterogeneity. This study aims to develop and validate a dynamic risk prediction model for PH by integra…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Adults aged 18 years or older
* Pulmonary artery systolic pressure (PASP) ≥35 mmHg as estimated by echocardiography
* Provided written informed consent
Exclusion Criteria:
* Severe hepatic or renal insufficiency
* Malignancy under active treatment
* Severe infection
* Active…
Contacts